Inflammaging: How Chronic Low-Grade Inflammation Drives Aging - and Where Peptides Fit

TL;DR

• Chronic, low-grade and sterile - a sustained inflammatory tone that builds over decades without a pathogen driving it; the term was coined by Claudio Franceschi and colleagues around 2000.
• Senescent cells are a main engine - they stop dividing but refuse to die, and secrete the SASP: a cocktail of inflammatory cytokines, chemokines and enzymes.
• Mitochondria and the gut wall feed it too - aging mitochondria leak DNA the immune system reads as bacterial, and a more permeable gut barrier lets microbial fragments into circulation.
• The markers are non-specific - hs-CRP, IL-6 and TNF-α move with a recent cold, a hard workout or poor sleep, so trends beat single readings; there is no validated "inflammaging score".
• These are associations, not proof - lowering a marker is not the same as preventing a disease, and inflammation is both contributor to and consequence of age-related illness.
• Fundamentals carry the evidence - sleep, exercise including resistance training, diet quality, reducing visceral fat and not smoking; peptides like KPV sit on top at a preclinical evidence tier.

Educational content, not medical advice. No doses or protocols appear; any use is physician-directed.

---

What "inflammaging" actually means

The word is a portmanteau - inflammation plus aging - coined by the immunologist Claudio Franceschi and colleagues around 2000 to describe a specific pattern. It is not the sharp, useful inflammation you get from a cut or a cold. It is a chronic, low-grade, systemic inflammatory tone that builds slowly over decades and persists in the background, measurable as modestly elevated inflammatory signals in the blood of otherwise healthy older adults.

Three features distinguish it. It is chronic, meaning it is a sustained baseline rather than a flare that resolves. It is low-grade, so the signal is a fraction of what you would see in acute illness - enough to matter over years, not enough to feel like being sick. And it is sterile, meaning it proceeds without an active pathogen driving it. The immune system is responding to something, but that something is increasingly the body's own accumulated wear rather than an outside invader.

That distinction - acute versus chronic - is the single most important idea to hold onto, because most consumer messaging blurs it.

Acute inflammation is a feature. Inflammaging is what happens when the system never fully stands down.

The drivers

There is no one cause. Inflammaging is better understood as the sum of several age-related processes that each feed inflammatory signaling. Two hubs are worth understanding because they connect to the rest of the longevity picture.

Cellular senescence and the SASP

As cells accumulate damage - from telomere shortening, DNA stress, and other insults - some stop dividing but refuse to die. These are senescent cells. In small numbers they are harmless; the problem is that they accumulate with age and adopt a senescence-associated secretory phenotype, or SASP, pumping out a cocktail of inflammatory cytokines, chemokines, and enzymes. The SASP is one of the most-cited engines of inflammaging: a relatively small population of these cells can raise the inflammatory tone of surrounding tissue and, over time, the whole body. This is why "senolytics" - compounds aimed at clearing senescent cells - have become an active research area, though that field remains early and is beyond the scope of this piece.

Mitochondrial dysfunction and gut-barrier changes

The second hub is metabolic and structural. As mitochondria age, they function less cleanly and can leak components - including mitochondrial DNA - that the immune system reads as danger signals, because that DNA resembles bacterial DNA to ancient parts of our immune wiring. This ties inflammaging directly to mitochondrial aging: the same organelle decline that saps energy also contributes to inflammatory signaling.

In parallel, the gut barrier tends to become more permeable with age, and the microbiome shifts toward a less favorable composition (dysbiosis). A leakier barrier lets more microbial fragments cross into circulation, where they provoke a low-grade immune response. Layer on the cumulative antigenic load of a lifetime - every infection, every exposure the immune system has had to manage - and you have a system that has been running its inflammatory programs for a very long time. None of these drivers acts alone; they compound.

Why it matters

Inflammaging earns attention because the same inflammatory signals show up, as associations, across the major diseases of aging. In cardiovascular disease, markers like hs-CRP and IL-6 are established components of risk prediction. In metabolic disease, chronic inflammation is intertwined with insulin resistance and type 2 diabetes. In frailty and sarcopenia, higher inflammatory markers track with muscle loss and physical decline, though the findings across studies are mixed rather than uniform. And in neurodegeneration, elevated inflammatory cytokines appear as a risk factor in conditions including Alzheimer's disease.

The honest framing matters here. These are associations, and inflammation is often both a contributor to and a consequence of these diseases - the arrows point both ways. Lowering an inflammatory marker is not the same as preventing a disease, and no responsible reading of the current evidence promises that it is. What the data support is that chronic inflammation is a meaningful, measurable part of the aging picture worth taking seriously - not a lever that, pulled alone, buys you extra years.

How you'd even measure it

If inflammaging is real, can you test for it? Partly. The commonly used markers are hs-CRP (high-sensitivity C-reactive protein), IL-6 (interleukin-6), and TNF-α (tumor necrosis factor-alpha). These are the workhorses of inflammation research and are used clinically in specific contexts, hs-CRP most established among them for cardiovascular risk.

The limitation is that all of them are non-specific. hs-CRP rises with a recent cold, a hard workout, poor sleep, obesity, or a dozen other things, which is why a single reading tells you little and trends over time tell you more. There is no single validated "inflammaging score" that a lab can hand you. Interpreting these numbers is a clinical judgment that accounts for context, not a consumer test to self-administer and act on.

This is where inflammaging connects to the broader question of biological age. Chronic inflammation is one of the inputs that shapes how "old" your body is functioning relative to your birthday, and some composite biological-age measures incorporate inflammatory signals. If you are interested in how aging is quantified beyond a single marker, epigenetic clocks cover that terrain - but treat all of these as research-grade tools for tracking, not diagnostic verdicts.

What's actually supported to lower it

Here is the part that is easy to skip and shouldn't be, because it is where the evidence is strongest by a wide margin. The best-supported levers against chronic inflammation are the boring ones.

Sleep. Poor and short sleep reliably raises inflammatory markers; consistent, adequate sleep is one of the most direct ways to lower baseline inflammatory tone.

Physical activity. Regular exercise, including resistance training to preserve muscle, is associated with lower chronic inflammation and directly counters the frailty pathway. Acute exercise raises inflammation briefly; the trained state lowers the baseline.

Diet quality. Dietary patterns higher in whole foods, fiber, and unsaturated fats - and lower in ultra-processed foods - are associated with lower inflammatory markers. The pattern matters more than any single "anti-inflammatory" food.

Reducing visceral fat. Abdominal (visceral) adipose tissue is metabolically active and pro-inflammatory. Reducing it is one of the more effective levers on chronic inflammation - and the depot responds to exercise and dietary change even when total body weight barely moves, which is why what actually reduces visceral fat is a different question from what reduces weight.

Not smoking. Smoking is a direct, sustained driver of systemic inflammation. Stopping is among the highest-value changes available.

None of this is exciting, and all of it is well-evidenced. For a fuller treatment of the practical steps, see the companion piece on the everyday drivers of inflammation and what to do about them.

Only after that foundation is in place does it make sense to ask where compounds fit. Certain peptides are studied for anti-inflammatory effects - KPV, a tripeptide fragment of the α-MSH hormone that appears to dampen NF-κB inflammatory signaling in preclinical models, and BPC-157, studied mainly for tissue repair. In a supervised longevity practice, peptides like KPV sit as a limited adjunct layered on top of the fundamentals, not a substitute for them, and only where a clinician judges it appropriate. The evidence tier here is the key point: the anti-inflammatory data for these peptides is largely preclinical and mechanistic, with limited or absent human randomized-controlled-trial evidence. They are best labeled investigational. That is a very different footing from sleep, exercise, and not smoking, and any honest account has to say so.

For readers approaching this from a chronic-illness angle rather than general aging, the overlap between inflammation, mast-cell activation, and post-viral syndromes is covered separately in peptides, long COVID, and MCAS.

The overreach to avoid

Because inflammaging is real and the word sounds scientific, it has become a marketing magnet. A few cautions.

"Anti-inflammatory" as a product claim is nearly meaningless on its own. Almost anything can be labeled anti-inflammatory in a petri dish or a mouse; that tells you little about whether it changes chronic inflammation in a living person over years. Ask what tier of evidence supports the claim.

Detoxes and cleanses do not address inflammaging. There is no toxin being flushed; the drivers are senescent cells, aging mitochondria, gut-barrier changes, and lifetime immune load - none of which respond to a juice protocol.

Chronic is not acute. Products that promise to "reduce inflammation" often borrow the language of acute inflammation - the swelling you can feel - to sell against a chronic process you cannot feel and that behaves differently. Suppressing inflammation is also not universally good; acute inflammation is protective, and blunting it indiscriminately is not the goal. The aim is to lower a maladaptive chronic baseline, carefully, not to switch inflammation off.

Frequently asked questions

What causes chronic inflammation with age? There is no single cause. Inflammaging is the combined output of several age-related processes: accumulation of senescent cells that secrete inflammatory signals (the SASP), mitochondrial dysfunction that leaks danger signals, increased gut-barrier permeability and microbiome shifts, and the cumulative immune load of a lifetime. It is a systems problem, which is why single-ingredient fixes underperform.

How do I know if I have it? You largely can't feel it, and there is no single definitive test. Clinicians use markers like hs-CRP, IL-6, and TNF-α, but these are non-specific and move with sleep, recent illness, exercise, and body composition. Trends over time interpreted in clinical context are more informative than any one reading. Some biological-age tools also fold in inflammatory signals. Testing and interpretation should be physician-directed, not self-diagnosed.

Do anti-inflammatory peptides work? The honest answer is that the evidence is early. Peptides such as KPV (an α-MSH fragment) and BPC-157 have mechanistic and preclinical support for anti-inflammatory and tissue-repair effects, but human randomized controlled trials are limited or lacking. They are best treated as investigational and, if used at all, only under medical supervision and layered onto the fundamentals - not as a first move or a substitute for them.

What lowers it most? The best-evidenced levers are unglamorous: adequate sleep, regular exercise including resistance training, a whole-food diet pattern, reducing visceral fat, and not smoking. These have far stronger support than any supplement or peptide for lowering chronic inflammation, and they are the foundation everything else is judged against.

Related reading

• The everyday drivers of inflammation and what to do about them
• Senolytics and "zombie cells" - senescent cells are one proposed source of the inflammatory signalling described here, and the clearance evidence is earlier than the marketing suggests
• What hs-CRP actually measures - the marker most often used to put a number on chronic inflammation, and the limits of a single reading
• KPV: the anti-inflammatory peptide explained
• How to reduce visceral fat
• Mitochondria and aging
• Epigenetic clocks and biological age
• Can anything actually move an epigenetic clock? - what the randomised evidence shows
• Peptides and autoimmune disease: why caution comes first - why immune modulation cuts both ways

Part of The Complete Guide to Inflammation

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore KPV.

---

This article is educational and does not constitute medical advice. No doses or protocols are provided. Peptides discussed are investigational, and any use should be supervised by a qualified physician. Individual circumstances vary; consult a clinician before making changes to your health regimen. Claims for the Malaysian market are subject to MAB requirements.

References

• Franceschi C, et al. Original description of inflamm-aging (Annals of the New York Academy of Sciences and subsequent reviews).
• Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases (Journals of Gerontology).
• Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (Nature Reviews Cardiology).
• Systematic review and meta-analysis of IL-6, TNF, and IL-1β in relation to age-related diseases (Frontiers in Immunology).
• Reviews of cellular senescence and the senescence-associated secretory phenotype (SASP) as drivers of inflammaging.
• Preclinical literature on KPV (α-MSH fragment) and NF-κB inhibition in models of intestinal and skin inflammation.
• Reviews of BPC-157 in tissue healing (preclinical).

Sources were confirmed via web search at the time of drafting; specific figures are intentionally omitted pending medical review. Full citations to be finalized at review.